{"id":"decavac","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or erythema"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Decavac contains antigens from Corynebacterium diphtheriae toxoid, Clostridium tetani toxoid, and Bordetella pertussis components that stimulate adaptive immune responses. The vaccine is formulated to provide booster protection in individuals previously primed with childhood diphtheria-tetanus-pertussis vaccines, maintaining or enhancing antibody titers against these three pathogens.","oneSentence":"Decavac is a recombinant vaccine designed to boost immune response against diphtheria, tetanus, and pertussis by providing booster immunization in adolescents and adults.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:08:53.087Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Booster immunization against diphtheria, tetanus, and pertussis in adolescents and adults"}]},"trialDetails":[{"nctId":"NCT05294588","phase":"PHASE2","title":"Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2022-04-18","conditions":"Gonorrhea Male","enrollment":65},{"nctId":"NCT01137435","phase":"PHASE4","title":"Post Marketing Surveillance for ADACEL™ in South Korea","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-06","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":659},{"nctId":"NCT00835237","phase":"PHASE3","title":"Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-02-17","conditions":"Tetanus, Acellular Pertussis, Diphtheria","enrollment":1332},{"nctId":"NCT01738477","phase":"PHASE3","title":"Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Previously Boosted Young Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-01-31","conditions":"Tetanus, Acellular Pertussis, Diphtheria","enrollment":165},{"nctId":"NCT00610168","phase":"PHASE4","title":"Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-01-01","conditions":"Acellular Pertussis, Tetanus, Diphtheria","enrollment":82},{"nctId":"NCT01294605","phase":"PHASE4","title":"Immunogenicity and Reactogenicity Study of BoostrixTM (dTpa) and Boostrix-IPV (dTpa-IPV)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-04","conditions":"Acellular Pertussis, Tetanus, Diphtheria","enrollment":460},{"nctId":"NCT00254995","phase":"","title":"Descriptive, Post-marketing, Surveillance Safety Study of Menactra Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2005-07","conditions":"Meningitis, Meningococcal Disease","enrollment":62626},{"nctId":"NCT00802867","phase":"PHASE4","title":"Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2004-02","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":989},{"nctId":"NCT00601835","phase":"PHASE4","title":"Canadian Manufactured Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine Compared With U.S. Manufactured Td","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2004-05","conditions":"Diphtheria, Tetanus","enrollment":3651},{"nctId":"NCT00662870","phase":"PHASE3","title":"Study of the Safety, Immunogenicity and Lot Comparability of DAPTACEL When Administered With Other Recommended Vaccine","status":"COMPLETED","sponsor":"Sanofi","startDate":"2001-05","conditions":"Diphtheria, Tetanus, Whooping Cough","enrollment":1941},{"nctId":"NCT01262924","phase":"PHASE3","title":"Study of Reduced-antigen-content Acellular Pertussis Vaccine and Diphtheria-Tetanus-Acellular Pertussis Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"1997-10","conditions":"Diphteria, Tetanus and Pertussis","enrollment":116}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Decavac™","genericName":"Decavac™","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"Decavac is a recombinant vaccine designed to boost immune response against diphtheria, tetanus, and pertussis by providing booster immunization in adolescents and adults. Used for Booster immunization against diphtheria, tetanus, and pertussis in adolescents and adults.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}